BioPharma Resources

Drug Trial Radar · NCT05701306

APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors

A Phase Ib-ⅡClinical Study of APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors

Last checked: Nov 19, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Feb 28, 2023

Primary completion

Jun 1, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Ascentage Pharma Group Inc.Industry
Sponsor type
Industry
Collaborators
Suzhou Yasheng Pharmaceutical Co., Ltd.
First posted
Jan 27, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 5 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open, non-randomized Phase Ib-II trial of dose-escalation and cohorts expansion to evaluate the safety, pharmacokinetic profile and initial efficacy of APG-115 alone or in combination with APG-2575 in the treatment of recurrent or refractory neuroblastoma or solid tumors.

Conditions

  • Neuroblastoma
  • Solid Tumor

Interventions

  • APG-115Drug

    Orally once every other day(QOD) for 2 weeks and suspended for 1 week, 21 days as a cycle.

  • APG-2575Drug

    Orally once a day (QD) for 21 days, 21 days as a cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limiting Toxicity (Phase I)Time frame: Up to 21 days
  2. Treatment-Emergent Adverse Events per NCI-CTCAE version 5.0Time frame: Up to 12 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

  • Tongji Hospital, Huazhong University of Science and Technology (HUST)

    Wuhan, Hubei, China · Recruiting

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.